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Mitochondrial fatty acid oxidation is considered to be important for energy homeostasis, especially under conditions requiring a high energy demand, such as fasting and infection (3) . Several reports have shown that endotoxins alter energy metabolism, including the augmentation of glucose and fatty acid utilization, most probably because of the high energy demand in endotoxemia and/or septic conditions (4 -7). However, excessive endotoxins impair the function of the mitochondria, which in turn results in impaired fatty acid utilization (8 -10) . Several symptoms such as multiple organ failure, hypoglycemia, hyperlipidemia, and liver steatosis are commonly observed in sepsis, endotoxemia, and fatty acid oxidation disorders, also known as the Reye-like syndrome, which is caused by both inheritable and heritable defects of mitochondrial fatty acid oxidation (11) (12) (13) (14) (15) . Despite those similar pathologies and the existence of individuals with insufficient fatty acid oxidation, the molecular mechanism and consequence of insufficient fatty acid oxidation in endotoxemia remain to be elucidated.
Thioredoxin binding protein-2 (TBP-2) was identified as a binding protein of thioredoxin-1 (TRX) by yeast twohybrid screening using TRX as bait (16) .
Objectives: Endotoxin triggers a reorganization of the energy metabolic pathway, including the promotion of fatty acid utilization to adapt to a high energy demand during endotoxemia. However, the factors responsible for the metabolic adaptation and characteristic pathologies resulting from defective utilization fatty acids during endotoxin response have not been fully clarified. The thioredoxin binding protein-2 (TBP-2) knockout (TBP-2 -/-) mouse is an animal model of fatty acid oxidation disorder. The aim of this study was to determine whether and how TBP-2 is involved in metabolic regulation in a lipopolysaccharide (LPS)-induced endotoxemia model in mice.
Design TBP-2 binds to TRX through the formation of a mixed disulfide (17) , which results in competitive inhibition of the other target molecules of TRX (16, 18) . Growing evidence has suggested that TBP-2 serves a wide range of biological functions, including tumor suppression, cellular development, and metabolic control (19 -21) . TBP-2 knockout (TBP-2 Ϫ/Ϫ ) mice have defective fatty acid utilization, thereby showing compatible phenotypes of human fatty acid oxidation disorders under fasting conditions (20, 22, 23) . We hypothesized that TBP-2 is involved in fatty acid oxidation in endotoxemia and therefore that TBP-2 Ϫ/Ϫ mice provide a suitable animal model to evaluate the sequential pathology resulting from the inability to utilize fatty acids during endotoxemia.
In the present study, we explored the role of TBP-2 in an animal model of endotoxemia using intraperitoneal injections of lipopolysaccharide (LPS), a cell wall component derived from Gramnegative bacteria, to TBP-2 Ϫ/Ϫ mice. Our results demonstrated that TBP-2 Ϫ/Ϫ mice showed a high mortality with pathologies partly similar to those shown in human septic patients, as well as fatty acid oxidation disorders after LPS administration, suggesting that the inability to utilize fatty acid is a crucial risk factor for mortality in endotoxemia.
MATERIALS AND METHODS

Animals
TBP-2
Ϫ/Ϫ mice were backcrossed for at least five generations to C57BL/6 backgrounds. All of the mice were housed in the specific-pathogen-free animal facility at the Institute for Virus Research, Kyoto University. All of the procedures involving animals were performed in accordance with the protocols approved by the Kyoto University Institutional Animal Care and Use Committee. TBP-2 -/-mice (20) were backcrossed for at least five generations to C57BL/6 (Clea Japan, Meguro Tokyo, Toyko, Japan).
Western Blot Analysis
The liver was dissected and lysed with lysis buffer containing 1% Nonidet P-40, 1% Na-deoxydulate, 0.1% sodium dodecyl sulfate, 20 mM Tris (pH 7.5), 5 mM ethylenediaminetetraacetic acid, 150 mM NaCl, protease inhibitors (Complete; Roche, Indianapolis, IN), and phosphatase inhibitors (PhosStop; Roche). Western blot analysis was performed using an ECL Western blotting detection system (Amersham Biosciences, Piscataway, NJ) according to the manufacturer's instructions. Anti-Akt, antiphosphorylated specific Akt (Ser473), antiFoxO1, and antiphosphorylated-specific FoxO1 (Ser256) were purchased from Cell Signaling (Danvers, MA). 
Induction of Endotoxemia
Histopathology
Under anesthesia, the liver and kidney were removed at appropriate time points, fixed in 10% buffered formalin, and embedded in paraffin, followed by staining with hematoxylin and eosin, periodic acid-Schiff, and anti-NIMP-R14 antibody (Abcam, Cambridge, MA).
Blood Biochemical Examination
Mice were injected with LPS in saline or saline alone, as mentioned. Blood was collected from the retro-orbital, and clarified serum samples were stored at Ϫ20°C for the biochemical examinations.
Enzyme-Linked Immunosorbent Assay Analysis
Mice were injected with LPS in saline or saline alone, as mentioned. Blood was collected from the retro-orbital at the indicated times, and clarified serum samples were stored at Ϫ80°C. Serum interferon-␥, interferon-␤, tumor necrosis factor-␣, interleukin-6, interleukin-10, monocyte chemoattractant protein-1, and macrophage inflammatory protein-2 levels were determined using ELISA 
Semiquantitative and Quantitative Reverse Transcription-Polymerase Chain Reaction Analysis
After LPS injection, the liver was removed, and the total RNA was extracted using TRIzol reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. Reverse transcription was performed with a SuperScript III First-Strand Synthesis System kit (Invitrogen, Carlsbad, CA). Real-time reverse transcription-polymerase chain reaction was performed using SYBR Premix Ex Tag (TAKARA, Otsu, Shiga, Japan). Polymerase chain reactions were performed using the following primers: TBP-2 sense (5Ј-GTGATG-GATCTAGTGGATGTC-3Ј), antisense (5Ј-TCACTGCACGTTGTTGTTG-3Ј), ␤-actin sense (5Ј-ATGGATGACGATATCGCTGCGCT-3Ј), and antisense (5Ј-TAGAAGCACTTGCGGTGCAC-GAT-3Ј). Amplification of the products was not saturated with the number of cycles we performed.
Statistics Analysis
Results were expressed as mean Ϯ SD. Statistical comparisons were performed by oneway analysis of variance, followed by StudentNewman-Keul's post hoc analysis. Survival data were evaluated using the Kaplan-Meier log-rank test. Findings of p Ͻ .05 were considered as statistically significant.
RESULTS
TBP-2 ؊/؊ Mice Are Susceptible to LPS-Induced Endotoxemia
To investigate the role of TBP-2 in response to LPS, wild-type, TBP-2 heterozygous knockout (TBP-2 ϩ/Ϫ ), and homozygous knockout (TBP-2 Ϫ/Ϫ ) mice were injected intraperitoneally with doses of 1, 5, or 25 mg/kg of body weight of LPS. As shown in Figure 1A , both male and female TBP-2 Ϫ/Ϫ mice showed a significant susceptibility to LPS compared with the wild-type mice in all of the doses we tested. Before death, these mice showed severe debility and hypothermia (data not shown). This susceptibility was also observed in imprinting control region and Balb/c genetic background TBP-2 Ϫ/Ϫ mice, suggesting that the high susceptibility to LPS does not depend on the genetic background of mice (Supplemental ϩ/Ϫ mice showed a tendency for high mortality compared to wild-type mice after LPS administration. Reverse transcriptionpolymerase chain reaction examination revealed that TBP-2 expression was upregulated in the liver after 1 hr after the LPS administration, and the expression was sustained for 24 hrs (Fig. 1B) . LPS-induced TBP-2 expression was attenuated in TBP-2 ϩ/Ϫ mice, compared to wild-type mice, suggesting that upregulated TBP-2 may partly contribute to animal survival in the response to LPS (Fig. 1C) . These results suggested that TBP-2 is an endotoxin response gene and plays an important role in animal survival in LPSinduced endotoxemia.
Hypercytokinemia Is Not Observed in LPS-Challenged TBP-2 ؊/؊ Mice
Because hypercytokinemia has been associated with high mortality in several animal models showing a high susceptibility to LPS, we then investigated whether there were any differences between wild-type and TBP-2 Ϫ/Ϫ mice in the LPS-induced production of inflammatory cytokines. The serum levels of tumor necrosis factor-␣, interleukin-6, interleukin-10, interferon-␤, interferon-␥, monocyte chemoattractant protein-1, and macrophage inflammatory protein-2 were measured after LPS injec- mice did not show higher levels of those cytokines compared to wild-type mice but rather slightly lower levels of interferon-␤ and monocyte chemoattractant protein-1 at particular time points. Consistent with cytokine and chemokine levels, neutrophil infiltrations were not significantly changed between the wild-type and TBP-2 Ϫ/Ϫ mice (Fig. 2B) . These results suggested that the high susceptibility of TBP-2 Ϫ/Ϫ mice was not associated with the enhancement of cytokine production.
Fat Accumulation in TBP-2 ؊/؊
Mice After LPS Injection
Histologic studies were performed to investigate the abnormality of TBP-2 In addition, the glomerular structure was destroyed in the kidneys of LPS-injected TBP-2 Ϫ/Ϫ mice (Fig. 3A) . Several serum markers were examined to investigate those organ injuries. As shown in Figure 3B , the levels of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, blood urea nitrogen, and creatinine were elevated in TBP-2 Ϫ/Ϫ mice by LPS injection, compared to wild-type mice, indicating liver and renal injuries. Endotoxin-induced organs ischemia occasionally accompanies organ injuries, but we could not find any ischemic necrosis in the livers and kidneys or reduced liver weight, an index of reduced liver blood flow in TBP-2 Ϫ/Ϫ mice (Supplemental 
Plasma Lipid Derivatives Are Accumulated in TBP-2 ؊/؊ Mice After LPS Injection
Because steatosis was found in the liver and kidney of TBP-2 Ϫ/Ϫ mice, we conducted examinations to determine whether the lipid metabolism was dysregulated in those mice. As shown in Figure 4 , the plasma levels of free fatty acids, triglycerides, total cholesterol, and phospholipids were increased in TBP-2 Ϫ/Ϫ mice, but not in wild-type mice, after LPS injection. LPSinduced hyperlipidemic features were also observed in the C57B/6 F12 genetic background of TBP-2 Ϫ/Ϫ mice ( Supplementary  Fig. IB , see Supplemental Digital Content 1, http://links.lww.com/CCM/A169). We have previously shown that these hyperlipidemic features were observed in TBP-2 Ϫ/Ϫ mice during a fasting state (20) . Interestingly, the increased levels of the lipid derivatives were significant in the LPS injection mice, rather than with fasting. In addition, TBP-2 mice showed a resistance against LPSinduced anorexia (Fig. 4B) , indicating that the dyslipidemia is not simply caused by LPS-induced anorexia in TBP-2 Ϫ/Ϫ mice. Thus, TBP-2 has an essential role in lipid homeostasis during LPS response. Notably, TBP-2 Ϫ/Ϫ mice show an insufficient fatty acid utilization (20) ; therefore, accumulated free fatty acids were observed in those mice without LPS injection or fasting.
Dysregulation of Glucose Metabolism Triggers the Fatality of LPS-Injected TBP-2 ؊/؊ Mice
Hypoglycemia is occasionally observed in endotoxemia. To investigate whether TBP-2 Ϫ/Ϫ mice have abnormalities in the glucose metabolism during LPS response, the serum levels of glucose and insulin were examined. Plasma glucose levels were reduced at 24 hrs after LPS injection in wild-type mice, whereas TBP-2 Ϫ/Ϫ mice showed more severe hypoglycemia (Fig. 5A ). Plasma levels of insulin were significantly upregulated in the TBP-2 Ϫ/Ϫ mice (Fig. 5B) . Periodic acidSchiff staining revealed that glycogen was depleted in the liver of TBP-2 Ϫ/Ϫ mice after LPS injection, compared to wildtype mice (Fig. 5C ), suggesting that accelerated glucose consumption attributable to hyperinsulinemia with insufficient fatty acid utilization is the more dominant constraint compared to insulin-mediated inhibition of glycogen catabolism.
To investigate the role of hypoglycemia in the observable mortality, we examined whether glucose supplementation reduces the lethality induced by LPS in TBP-2 Ϫ/Ϫ mice. As shown in Figure  5D , lethality was not reduced in LPSchallenged TBP-2 Ϫ/Ϫ mice when these mice were housed with 20% glucose available in drinking water. In contrast, lethality was reduced in these mice by an intraperitoneal injection of glucose. Thus, forced glucose supplementation reduces the LPS-induced lethality in TBP-2 Ϫ/Ϫ mice. Taken together, these data indicate that LPS-induced hypoglycemia is a major cause of death in TBP-2 Ϫ/Ϫ mice.
Insulin Signaling Is Activated After LPS Challenge in TBP-2 ؊/؊ Mice
Insulin promotes hypoglycemia through the induction of glucose uptake ) mice after lipopolysaccharide (LPS) administration or fasting. Serum levels of free fatty acid, triglyceride, total cholesterol, and phospholipids were examined at the indicated time points after LPS administration or fasting. The numbers of mice examined were three to ten (free fatty acids), three to 14 (triglycerides), three to ten (total cholesterol), and three to ten (phospholipids) in each experimental group. B, Amount of food intake of TBP-2 Ϫ/Ϫ mice after LPS administration. TBP-2 Ϫ/Ϫ and wild-type mice were injected with LPS. The amount of food intake per 24 hrs was examined at the indicated time points. At least three mice that survived at the indicated time points were examined for each experimental group. and the inhibition of gluconeogensis, which are mediated by Akt kinase. To investigate whether LPS-induced hyperinsulinemia activates Akt kinase, the phosphorylation levels of Akt were examined. As shown in Figure 6A , LPS challenge significantly induced Akt phosphorylation in TBP-2 Ϫ/Ϫ mice compared to the wild-type mice. Akt phosphorylates and inhibits FoxO1, a crucial transcription factor promoting gluconeogenesis (24) . As is consistent with the activation of Akt, phosphorylation levels of FoxO1 were upregulated in TBP-2 Ϫ/Ϫ mice after LPS injection (Fig. 6B) . These results suggested that LPS-induced hyperinsulinemia activates insulin signaling to enhance hypoglycemia in TBP-2 Ϫ/Ϫ mice during LPS response.
DISCUSSION
In our present study, we reported that TBP-2 Ϫ/Ϫ mice showed a high susceptibility to LPS-induced lethality. Because the TBP-2 Ϫ/Ϫ mouse is an animal, fatty acid oxidation disorders model (20) , our data strongly suggested that insufficient fatty acid utilization is a risk factor for mortality during endotoxemia. TBP-2 Ϫ/Ϫ mice showed pathologic features after LPS administration, such as fat infiltration into the liver and kidneys, multiple organ injuries, elevations of plasma lipid derivatives, hyperinsulinemia, and hypoglycemia, which are most certainly enhanced by the inability for fatty acid utilization, resulting from the loss of TBP-2. Several characteristic features have also been reported in human patients with sepsis and fatty acid oxidation disorders (12, 25, 26) . Recently, it was reported that dysregulations of mitochondrial protein synthesis and gene expression were often observed in septic patients treated in an intensive care unit (27) . Taken together, those mitochondrial dysfunctions might be not only the resultant pathology but also a deterioration factor in endotoxemia. The LPS-induced pathology of TBP-2 Ϫ/Ϫ mice were quite similar to fasting mice, such as multiple organ injuries and liver and renal steatosis (Fig. 3A and Supplementary Fig. IV , see Supplemental Digital Content 4, http://links.lww.com/CCM/A172), high levels of plasma lipid derivatives (Fig. 4A) , hyperinsulinemia, and hypoglycemia (20, 28) . Glucose supplementation also rescues fasting-induced abnormalities in TBP-2 Ϫ/Ϫ mice such as mortality and increased plasma levels of aspartate aminotransferase, alanine aminotransferase, and creatinine (20) . Even though the triggering factor is different between fasting and LPS administration, most of the abnormalities seem to be similar. As is the case with TBP-2 Ϫ/Ϫ mice, it has been reported that hyperinsulinemia associates with hypoglycemia in patients with Reye-like syndrome harboring mutation in medium-chain and short-chain l-3-hydroxy-acyl-CoA dehydrogenase (29) . It is likely that inability of fatty acid utilization augments glucose consumption to adapt high energy demand, which is enhanced by insulin. Although insulin is supposed to inhibit glycogen catabolism, glycogen was significantly depleted, but not enough to normalize hypoglycemia in TBP-2 Ϫ/Ϫ mice. These results suggested that glucose is predominantly utilized during endotoxemia in circumstances in which fatty acid is not available as an energy source because of impaired fatty acid catabolism. Even though it is currently unknown if hyperinsulinemia is associated with hypoglycemia or exacerbates abnormalities in endotoxemia, our data strongly suggested that hyperinsulinemia resulting in hypoglycemia is a critical risk factor in patients having insufficient fatty acid utilization.
In conclusion, this study suggests that mitochondrial function inability is a risk factor for mortality in endotoxemia and that the resultant pathologic features are multiorgan injury, hypoglycemia, and dyslipidemia without significant changes in cytokine levels. Because mitochondrial function is disturbed by inborn defects and by an infection itself, these findings may be a good clue to develop novel therapeutic treatment for improving mortality in human patients. Although it remains unclear whether TBP-2 has a role in endotoxin-induced fatal syndrome after an infection in humans, our present study provides some intriguing implications and the possibility that TBP-2 is involved in such biological responses. Hence, TBP-2 may be a novel target molecule for therapeutic approaches for use in human diseases. 
